Burkhard Riemann

Background: Thyroid nodules are highly prevalent, affecting up to 75% of the population, yet most are benign. The limited specificity of ultrasound-based workup leads to substantial overdiagnosis and overtreatment, underscoring the need for improved imaging-based classification. Diffusion-weighted MRI (DWI), quantified via the apparent diffusion coefficient (ADC), has emerged as a promising imaging biomarker. This meta-analysis updates pooled diagnostic performance metrics and systematically evaluates which DWI acquisition techniques, imaging parameters, and combinations with other MRI modalities are most promising for clinical translation. Methods: PubMed, Web of Science, Scopus, and ProQuest were systematically searched. Pooled sensitivity, specificity, and area under the curve (AUC) were calculated using bivariate random-effects models. The effects of b-value, magnetic field strength, echo time, and diffusion model on diagnostic accuracy and ADC values were examined through subgroup and meta-regression analyses. Results: Forty-six studies (3003 nodules) were included. Pooled sensitivity and specificity were 0.84 (95% CI: 0.81–0.86) and 0.88 (95% CI: 0.85–0.90), with an AUC of 0.912. Intravoxel incoherent motion and diffusion kurtosis imaging showed no added value over the mono-exponential model. For the mono-exponential model, a negative association between b-values and reported ADCs was observed, whereas no association was found between b-values and diagnostic accuracy. Magnetic field strength and echo time did not affect ADCs. Combining DWI with morphological imaging showed the potential to further enhance diagnostic performance. Conclusions: DWI holds strong potential to improve the diagnostic workup of thyroid nodules. Technical standardization, particularly of key acquisition parameters, should be pursued to enable clinical implementation.

Background: Thyroid nodules are common yet remain a diagnostic challenge. While ultrasound and Thyroid Imaging Reporting and Data Systems (TIRADS) are accepted as standard, the use of thyroid scintigraphy in euthyroid patients is debated. The European Association of Nuclear Medicine advocates it, whereas the American Thyroid Association and European Thyroid Association do not. However, it has not been evaluated whether scintigraphy adds value to TIRADS in a multimodal approach. Our study addresses this gap by assessing the impact of integrated pertechnetate scintigraphy on TIRADS accuracy. Methods: The diagnostic performance of ACR-TIRADS, EU-TIRADS, pertechnetate scintigraphy, and multimodal models were retrospectively analyzed for 322 nodules (231 benign, 91 malignant) in 208 euthyroid patients with histopathology as a reference. Generalized estimating equations were used for statistical analysis. Results: On scintigraphy, 210 nodules were hypofunctional, 99 isofunctional, and 13 hyperfunctional. The AUC for thyroid scintigraphy, ACR-TIRADS, and EU-TIRADS were 0.6 (95% CI: 0.55–0.66), 0.83 (95% CI: 0.78–0.88), and 0.78 (95% CI: 0.72–0.83). Integrating scintigraphy with ACR-TIRADS and EU-TIRADS slightly increased diagnostic accuracy (AUC 0.86 vs. 0.83, p = 0.039 and AUC 0.80 vs. 0.78, p = 0.008) and adjusted the malignancy probability for intermediate risk TIRADS categories, with iso- or hyperfunctioning nodules in ACR-TIRADS-TR4 or EU-TIRADS-4 showing comparable malignancy probabilities as hypofunctioning nodules in TR3 or EU-TIRADS-3, respectively. Conclusions: Integrating thyroid scintigraphy with ACR- or EU-TIRADS moderately improves diagnostic performance, potentially benefiting management, especially in complex cases like multinodular goiter or indeterminate FNA. Further research is warranted to validate these findings and explore their clinical implications.

In rare diseases such as adrenocortical carcinoma (ACC), in silico analysis can help select promising therapy options. We screened all drugs approved by the FDA and those in current clinical studies to identify drugs that target genomic alterations, also known to be present in patients with ACC. We identified FDA-approved drugs in the My Cancer Genome and National Cancer Institute databases and identified genetic alterations that could predict drug response. In total, 155 FDA-approved drugs and 905 drugs in clinical trials were identified and linked to 375 genes of 89 TCGA patients. The most frequent potentially targetable genetic alterations included TP53 (20%), BRD9 (13%), TERT (13%), CTNNB1 (13%), CDK4 (7%), FLT4 (7%), and MDM2 (7%). We identified TP53-modulating drugs to be possibly effective in 20–26% of patients, followed by the Wnt signaling pathway inhibitors (15%), Telomelysin and INO5401 (13%), FHD-609 (13%), etc. According to our data, 67% of ACC patients exhibited genomic alterations that might be targeted by FDA-approved drugs or drugs being tested in current clinical trials. Although there are not many current therapy options directly targeting reported ACC alterations, this study identifies emerging options that could be tested in clinical trials.

Zusammenfassung Hintergrund Bösartige Schilddrüsentumoren sind die häufigsten bösartigen endokrinen Tumoren, die ungefähr 1 % aller malignen Tumoren umfassen. In den letzten Jahren ist die Inzidenz des differenzierten Schilddrüsenkarzinoms (DTC) deutlich angestiegen, insbesondere der kleinen papillären Karzinome. Fragestellung Dargestellt werden Indikationen und Ergebnisse der Radiojodtherapie (RJT) beim DTC. Material und Methoden Es erfolgt die Durchsicht der aktuellen Literatur und Leitlinien zur RJT des DTC. Ergebnisse Die RJT stellt die wichtigste adjuvante Behandlungsoption des DTC dar und wird generell gut vertragen. Schlussfolgerungen Verglichen mit anderen Tumoren hat das DTC durch die Kombination von Operation und RJT eine sehr gute Prognose mit einer durchschnittlichen Überlebensrate von über 90 %.